Evidence map›Paper›PMID 31885610›Full record

ArticleStem cells international2019

Systemic Infusion of Expanded CD133

Addeli B B Angulski, Luiz Guilherme A Capriglione, Fabiane Barchiki, Paulo Brofman, Marco A Stimamiglio, Alexandra C Senegaglia, Alejandro Correa

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Clinical applications of stem cell-derived exosomes.Signal transduction and targeted therapy · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Addeli B B Angulski *Carlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba 81350-010, Brazil.ORCID https://orcid.org/0000-0002-4636-5457
Luiz Guilherme A Capriglione *Core for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, Brazil.
Fabiane BarchikiCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, Brazil.
Paulo BrofmanCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, Brazil.
Marco A StimamiglioCarlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba 81350-010, Brazil.
Alexandra C SenegagliaCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, Brazil.ORCID https://orcid.org/0000-0002-8052-6357
Alejandro CorreaCarlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba 81350-010, Brazil.ORCID https://orcid.org/0000-0002-5887-1453
Pontifícia Universidade Católica do Paraná · BRFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial infarction is a leading cause of death among all cardiovascular diseases. Cell therapies using a cell population enriched with endothelial progenitor cells (EPCs), expanded CD133

Identifiers

PMID31885610
PMCPMC6914904
OpenAlexW2993506337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.